Business Wire

BridgeTower Capital Teams with Securitize and Chainlink to Expand Offerings in Staking, DeFi and Permissioned Markets on Avalanche

Share

BridgeTower Capital, an innovator in connecting blockchain markets globally, is partnering with Securitize, the leader in digital assets securities, to launch the BridgeTower Global Platform offering for Permissioned Markets. BridgeTower is also launching a Staked Digital Asset Security (SDAS) that will run in an Avalanche subnet.

BridgeTower is partnering with Securitize, its digital transfer agent, to offer its products through a seamless user interface. Investors simply need to create a Securitize iD, in which their identity is verified consistent with U.S. regulatory standards. They can then invest easily in opportunities across the BridgeTower ecosystem, as well as Securitize’s own offerings, including shares in private companies and institutional grade funds.

Transactions will utilize smart contracts and regulated custodians will provide transparency around asset collateralization using Chainlink Proof of Reserve, the market-leading oracle solution for auditing on-chain and off-chain reserves. Using Chainlink Proof of Reserve to verify the collateral of wrapped tokens across the multi-chain ecosystem, BridgeTower’s Permissioned Markets will unlock asset liquidity across many of the world’s most significant blockchains.

BridgeTower’s Permissioned markets will include DeFi financial products such as customized blockchain staking opportunities, token swaps and NFT development with arts, entertainment, and sporting ventures to provide seamless, institutionally compliant products.

With more than 5,000 of its own Staking Nodes, BridgeTower utilizes renewable energy to reduce the carbon footprint. Already a leading proof-of-stake infrastructure provider for leading Layer 1 blockchains and Web 3.0 companies, BridgeTower has built its fast-growing foundational staking and DeFi business through partnerships and investments over the past few years.

“We are bridging the value of innovative blockchain staking and DeFi products seamlessly to institutional investors,” said BridgeTower CEO Cory Pugh. “We have worked tirelessly to bring innovation and regulated processes by using our staking and DeFi products in Permissioned Markets to create a compliant gateway for institutions to participate in the evolving blockchain opportunity.”

“There is significant institutional demand to participate in DeFi opportunities, but the lack of safe places to participate has kept institutions on the sidelines. Now that Securitize is offering permissioned DeFi through on-chain attestations, as well as through our partnership with Avalanche to build a permissioned subnet, the doors to regulated DeFi have opened,” said Jamie Finn, president, and co-founder of Securitize. “The globally integrated platform BridgeTower has created will enable more institutions to enter the market confidently.”

AVAX STAKED DIGITAL ASSET SECURITY TO LAUNCH

"Avalanche has rapidly become the preferred destination for institutions to access the innovation emerging from decentralized finance and contribute their own expertise in creating products and ecosystems of value on-chain. I'm excited to see BridgeTower and Securitize expanding their involvement in the Avalanche community and building institutional-grade applications," said John Nahas, VP of Business Development at Ava Labs.

BridgeTower’s most recent product innovation is a Staked Digital Asset Security. The new security will receive staking rewards, and after one year’s hold time can be traded in the Permissioned Market. The AVAX Staking Security token will represent staked AVAX utilizing Smart Contracts, to mint staked utility tokens on the Avalanche Chain and run across a subnet. This will create a single digital asset security designed for institutional investors capable of administering KYC, whitelisting, cap table management and reporting. BridgeTower will launch additional products later this year.

The Digital Staking Asset AVAX Security will also be offered on the Securitized Markets Alternative Trading System making it available to a wide range of accredited investors. Currently, there are more than 400,000 investors participating in Securitize Markets. Eventually, it is expected that the AVAX Staked Digital Asset Security, and other Institutional-grade staking securities will also be offered on Layer 1, Web 3.0, and eventually other exchanges.

“We believe this product is unique, as a security, and will be attractive to institutional investors who are looking for a regulated, global security to participate in the dramatically expanding blockchain proof-of-stake market,” Pugh added. “We are thrilled to partner with Securitize and Avalanche and for the expertise they bring as industry leaders in their respective areas.”

About BridgeTower

BridgeTower Capital has developed a global platform to uniquely bring products to its own permissioned markets to seamlessly enable an institutional gateway to staking, DeFi, NFT and Web 3.0 entities. BridgeTower operates more than 5,000 of its own staking nodes and owns servers utilizing 100 percent renewable energy. Significant portions of returns from these products are reinvested to continually grow BridgeTower’s infrastructure and assets. BridgeTower is a global company based in Singapore with operating entities in Switzerland and the United States allowing it to compliantly address many of the most important jurisdictions in the global economy. Learn more at http://www.bridgetowercapital.com.

About Securitize

Securitize is a digital asset securities firm with a mission to provide stakeholders access to invest in and trade alternative investments, and for companies to raise capital, manage shareholders, and offer shareholders potential liquidity. Securitize has pioneered a fully digital, end-to-end platform for issuing, managing, and trading digital asset securities, consistent with the existing U.S. regulatory framework, with over 1.2 million investor accounts and 3,000 businesses connected. Securitize is comprised of Securitize, Inc. and its subsidiaries Securitize, LLC (an SEC-registered transfer agent), Securitize Capital, LLC, Securitize Markets, LLC (an SEC-registered broker-dealer, member of FINRA and SIPC, and operator of the company’s alternative trading system), and Pacific Stock Transfer. Learn more at http://www.securitize.io.

About Avalanche

Avalanche is the fastest smart contracts platform in the blockchain industry, as measured by time-to-finality. Avalanche is blazingly fast, low cost, and eco-friendly. Any smart contract-enabled application can outperform its competition by deploying on Avalanche. Don’t believe it? Try an app on Avalanche today.

Securitize Disclosures

Securities offered on the Securitize Markets ATS have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Assets listed herein, such as digital assets or tokens using blockchain, are speculative, involve a high degree of risk, are generally illiquid, may have no value, have limited regulatory certainty, are subject to potential market manipulation risks and may expose investors to loss of principal. Blockchain investing involves a degree of risk that can be different from traditional markets. These risks include, but are not limited to, risk of regulatory uncertainty, market adoption, market manipulation, market exiting, price volatility and security risk. Investments in private placements, start-up investments in particular, are also speculative and involve a high degree of risk. Investors must be able to afford the loss of their entire investment. Eligibility to buy and sell securities on the Securitize Markets ATS is determined by Securitize Markets in its sole discretion. Offers to sell, or the solicitations of offers to buy any security can only be made through official offering documents that contain important information about risks, fees and expenses associated with the applicable securities available for trading on the Securitize Markets ATS. Investors should conduct their own due diligence, and are encouraged to consult with a financial advisor, attorney, accountant, tax advisors, and any other professional that can help you to understand and assess the risks associated with any investment opportunity. Past performance is not indicative of future results. There is no guarantee that a diversified portfolio will enhance overall returns, outperform a non-diversified portfolio, or prevent against loss

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

BridgeTower: Todd Wolfenbarger, todd@bridgetowercapital.com
Securitize: Evan Wagner, evan.wagner@securitize.io
Avalanche: Jay Kurahashi-Sofue, jay@avalabs.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye